These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33682031)

  • 1. Preformulation and characterization of raloxifene-loaded lipid nanoparticles for transdermal administration.
    Alves GL; Teixeira FV; da Rocha PBR; Krawczyk-Santos AP; Andrade LM; Cunha-Filho M; Marreto RN; Taveira SF
    Drug Deliv Transl Res; 2022 Mar; 12(3):526-537. PubMed ID: 33682031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers.
    Murthy A; Ravi PR; Kathuria H; Malekar S
    Nanomaterials (Basel); 2020 May; 10(6):. PubMed ID: 32486508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application.
    Mahmood S; Taher M; Mandal UK
    Int J Nanomedicine; 2014; 9():4331-46. PubMed ID: 25246789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal.
    Elsheikh MA; Elnaggar YS; Gohar EY; Abdallah OY
    Int J Nanomedicine; 2012; 7():3787-802. PubMed ID: 22888234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
    Khan S; Baboota S; Ali J; Narang RS; Narang JK
    Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tadalafil-loaded nanostructured lipid carriers using permeation enhancers.
    Baek JS; Pham CV; Myung CS; Cho CW
    Int J Pharm; 2015 Nov; 495(2):701-9. PubMed ID: 26423175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.
    Jain A; Sharma T; Kumar R; Katare OP; Singh B
    Drug Deliv Transl Res; 2022 May; 12(5):1136-1160. PubMed ID: 33966178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles.
    Elnaggar YS; El-Massik MA; Abdallah OY
    Int J Nanomedicine; 2011; 6():3195-205. PubMed ID: 22238508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioadhesive polymer/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability.
    Du X; Gao N; Song X
    Drug Deliv; 2021 Dec; 28(1):252-260. PubMed ID: 33501870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of Salicylic Acid Loaded Nanostructured Lipid Carriers Using Box-Behnken Design: Optimization, Characterization and Physicochemical Stability.
    Pantub K; Wongtrakul P; Janwitayanuchit W
    J Oleo Sci; 2017; 66(12):1311-1319. PubMed ID: 29199206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration.
    Song A; Zhang X; Li Y; Mao X; Han F
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1308-14. PubMed ID: 26707734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanostructured Lipid Carrier-Based Codelivery of Raloxifene and Naringin: Formulation, Optimization, In Vitro, Ex Vivo, In Vivo Assessment, and Acute Toxicity Studies.
    Alhalmi A; Amin S; Khan Z; Beg S; Al Kamaly O; Saleh A; Kohli K
    Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene encapsulated spanlastic nanogel for the prevention of bone fracture risk via transdermal administration: Pharmacokinetic and efficacy study in animal model.
    Ansari MD; Shafi S; Pandit J; Waheed A; Jahan RN; Khan I; Vohora D; Jain S; Aqil M; Sultana Y
    Drug Deliv Transl Res; 2024 Jun; 14(6):1635-1647. PubMed ID: 37996726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QbD-based optimization of raloxifene-loaded cubosomal formulation for transdemal delivery: ex vivo permeability and in vivo pharmacokinetic studies.
    Gupta T; Kenjale P; Pokharkar V
    Drug Deliv Transl Res; 2022 Dec; 12(12):2979-2992. PubMed ID: 35462597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema.
    Gao S; Tian B; Han J; Zhang J; Shi Y; Lv Q; Li K
    Int J Nanomedicine; 2019; 14():6135-6150. PubMed ID: 31447556
    [No Abstract]   [Full Text] [Related]  

  • 16. QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies.
    Pant A; Sharma G; Saini S; Kaur G; Jain A; Thakur A; Singh B
    Drug Deliv Transl Res; 2024 Mar; 14(3):730-756. PubMed ID: 37768530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: Effect of cyclodextrin complexation.
    Mennini N; Cirri M; Maestrelli F; Mura P
    Int J Pharm; 2016 Dec; 515(1-2):684-691. PubMed ID: 27825863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
    Saini D; Fazil M; Ali MM; Baboota S; Ali J
    Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of lipid nanoparticles and iontophoresis for enhanced lopinavir skin permeation: Impact of electric current on lipid dynamics.
    Moura RBP; Andrade LM; Alonso L; Alonso A; Marreto RN; Taveira SF
    Eur J Pharm Sci; 2022 Jan; 168():106048. PubMed ID: 34699938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance.
    Ahmed OA; Badr-Eldin SM
    Int J Nanomedicine; 2018; 13():6325-6335. PubMed ID: 30349253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.